GeneDx announced that it is expanding access to its rapid whole genome sequencing (rWGS) services in neonatal intensive care units (NICUs) with leading health systems through a new collaboration with Epic. The integration with Epic expands GeneDx's commercial strategy by connecting directly with health systems that use Epic's EHR to receive orders and send results. Patients will now have rWGS results seamlessly integrated into their single, comprehensive medical record, enabling providers to deliver more comprehensive patient care.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.44 USD | -0.07% | -1.08% | +897.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+897.82% | 718M | |
-16.52% | 8.49B | |
+67.04% | 4.29B | |
-2.45% | 2.63B | |
+6.11% | 2.68B | |
-56.94% | 1.73B | |
-18.60% | 1.68B | |
-20.40% | 1.45B | |
+15.38% | 1.19B | |
-50.40% | 1.01B |
- Stock Market
- Equities
- WGS Stock
- News GeneDx Holdings Corp.
- GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients